Advertisement

Reply to Letter to the Editor Regarding “The Importance of Diagnosing Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Based on the Defined Criteria”

  • Antoine EskanderEmail author
  • Stephen F. Hall
  • Marosh Manduch
  • Rebecca Griffiths
  • Jonathan C. Irish
Endocrine Tumors
  • 9 Downloads

Dear Editor,

We thank Dr. Rosario for his letter, which stimulates discussion around this important new diagnostic entity. We agree with Dr. Rosario’s point that improvements in methodology would result if there were a secondary review of all pathology specimens in the study;1however, this is both not feasible and also not necessary to demonstrate our main conclusion. The added benefit of our current methodology is that it provides a unique dataset with long-term survival that would otherwise not be possible in most retrospective studies. Given the long-term survival and its importance in studying noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), many of the cell blocks and histology slides would realistically no longer be available. The recommendation against the diagnosis being made on the original pathology report by the American Association of Clinical Endocrinologists (AACE) and the American Head and Neck Society (AHNS), quoted by Dr. Rosario,...

Notes

References

  1. 1.
    Eskander A, Hall SF, Manduch M, Griffiths R, Irish JC. A population-based study on NIFTP incidence and survival: is NIFTP really a “benign” disease? Ann Surg Oncol. 2019;26(5):1376–1384.CrossRefGoogle Scholar
  2. 2.
    Baloch ZW, Harrell RM, Brett EM, Randolph G, Garber JR; AACE Endocrine Surgery Scientific Committee and Thyroid Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state commentary: managing thyroid tumors diagnosed as noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Endocr Pract. 2017;23(9):1150–1155.Google Scholar
  3. 3.
    Ferris RL, Nikiforov Y, Terris D, et al. AHNS series: do you know your guidelines? AHNS endocrine section consensus statement: state-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Head Neck. 2018;40(9):1881–1888.CrossRefGoogle Scholar
  4. 4.
    Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–1029.CrossRefGoogle Scholar
  5. 5.
    Lloyd RV, Asa SL, LiVolsi VA, et al. The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Hum Pathol. 2018;74:1–4.CrossRefGoogle Scholar
  6. 6.
    Nouraei SA, Virk JS, Middleton SE, et al. A national analysis of trends, outcomes and volume-outcome relationships in thyroid surgery. Clin Otolaryngol. 2017;42(2):354–365.CrossRefGoogle Scholar
  7. 7.
    Al-Qurayshi Z, Robins R, Hauch A, Randolph GW, Kandil E. Association of surgeon volume with outcomes and cost savings following thyroidectomy: a national forecast. JAMA Otolaryngol Head Neck Surg. 2016;142(1):32–39.CrossRefGoogle Scholar
  8. 8.
    Hall SF, Irish JC, Groome PA, Urbach DR. Practice patterns in the management of patients with differentiated thyroid cancer in Ontario Canada 2000-2008. J Otolaryngol Head Neck Surg. 2014;43:29.CrossRefGoogle Scholar
  9. 9.
    Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol. 2017;30(6):810–825.CrossRefGoogle Scholar
  10. 10.
    Aburjania Z, Jang S, Montemayor-Garcia C, et al. Encapsulated follicular variant of papillary thyroid cancer: are these tumors really benign? J Surg Res. 2017;216:138–142.CrossRefGoogle Scholar
  11. 11.
    Parente DN, Kluijfhout WP, Bongers PJ, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: is NIFTP truly benign? World J Surg. 2018;42(2):321–326.CrossRefGoogle Scholar
  12. 12.
    Haugen BR, Sawka AM, Alexander EK, et al. American thyroid association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27(4):481–483.CrossRefGoogle Scholar
  13. 13.
    Chereau N, Greilsamer T, Mirallie E, et al. NIFT-P: are they indolent tumors? Results of a multi-institutional study. Surgery. 2019;165(1):12–16.Google Scholar
  14. 14.
    Rosario PW, Silva TH, de Oliveira PHL. Impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on the risk of malignancy estimated by the ultrasonographic classification of the American Thyroid Association (ATA) in thyroid nodules > 1 cm. Endocrine. 2018;60(3):535–536.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Antoine Eskander
    • 1
    • 2
    • 3
    Email author
  • Stephen F. Hall
    • 2
    • 3
    • 4
  • Marosh Manduch
    • 5
  • Rebecca Griffiths
    • 2
    • 3
  • Jonathan C. Irish
    • 6
  1. 1.Department of Otolaryngology – Head and Neck Surgery, Sunnybrook Health Sciences Centre and the Odette Cancer Centre, Michael Garron Hospital, Endocrine SurgeryUniversity of TorontoTorontoCanada
  2. 2.Institute for Clinical Evaluative Sciences (ICES)TorontoCanada
  3. 3.Cancer Care and EpidemiologyQueen’s UniversityKingstonCanada
  4. 4.Department of Otolaryngology – Head and Neck SurgeryQueen’s UniversityKingstonCanada
  5. 5.Department of Pathology and Laboratory SciencesQueen’s UniversityKingstonCanada
  6. 6.Department of Otolaryngology – Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer CentreUniversity of TorontoTorontoCanada

Personalised recommendations